The document provides guidelines for pharmaceutical companies on using social media. It includes sections on how pharma should engage with physicians and patients on social media, as well as guidelines for using specific platforms like Wikipedia, Facebook, Twitter, blogs and YouTube. The introduction explains that the guidelines were created collaboratively by experts to facilitate online interactions within the pharma industry, in the absence of official FDA guidance. Key principles outlined include being transparent, clarifying intent, understanding medicine licenses, facilitating adverse event reporting and more.